Is Healthcare Global Enterprises a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Healthcare Global Enterprises Ltd is a average quality company .

Is Healthcare Global Enterprises undervalued or overvalued?

The key valuation ratios of Healthcare Global Enterprises Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Healthcare Global Enterprises share price return in the past 10 years?

Data is not available for this company

Is Healthcare Global Enterprises a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Healthcare Global Enterprises Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the P/E ratio of Healthcare Global Enterprises?

The latest standalone P/E ratio of Healthcare Global Enterprises as of 20-Dec-2024 is 215.81.

What is the P/B ratio of Healthcare Global Enterprises?

The latest standalone P/B ratio of Healthcare Global Enterprises as of 20-Dec-2024 is 6.06.

What is the 52-week high and low of Healthcare Global Enterprises?

The 52-week high of Healthcare Global Enterprises is Rs. 553.25 and the 52-week low is Rs. 310.10.

Healthcare Global Enterprises Ltd - Stock Valuation and Financial Performance

Name: Healthcare Global Enterprises
Brand: Healthcare Global Enterprises

BSE: 539787 | NSE: HCG | Hospital & Healthcare Services | Small Cap

Place order

HealthcareGlobal Share Price

₹531.30 -10.90 -2.01%
as on 20-Dec'24 16:59

10 Year X-Ray of HealthcareGlobal:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	4.4%	4%	6.1%	7.7%	6.1%	1.6%	-12.6%	10.5%	8%	7.2%	-
Value Creation Index ⓘ	-0.7	-0.7	-0.6	-0.5	-0.6	-0.9	-1.9	-0.3	-0.4	-0.5	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	420	471	545	586	641	688	609	850	1,006	1,099	1,146
Sales YoY Gr.	-	12.1%	15.7%	7.6%	9.3%	7.5%	-11.6%	39.6%	18.3%	9.3%	-
Adj EPS ⓘ	0.1	-0.2	2.3	2	0.8	-6.1	-15.3	-3.7	2.9	2.4	2.5
YoY Gr.	-	-520%	NA	-11.1%	-61%	-883.3%	NA	NA	NA	-18.4%	-
BVPS (₹) ⓘ	38.2	61	63.5	69.6	72.7	68.5	69.7	78.5	81.5	84.1	87.6
Adj Net Profit ⓘ	0.4	-1.8	19.3	17.4	6.9	-54.2	-192	-51.3	40.7	33.3	34
Cash Flow from Ops. ⓘ	50.5	57.8	53.9	66.4	87	86.3	70.9	124	130	195	-
Debt/CF from Ops. ⓘ	6.2	3.4	4	4	4.9	5.7	3.4	0.9	0.9	2	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	11.3%	11.4%	21.8%	9.3%
Adj EPS ⓘ	53.7%	25.1%	NA	-18.4%
BVPSⓘ	9.2%	3%	6.5%	3.2%
Share Price	-	39.8%	31.9%	45.9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	0.1	-0.5	3.6	2.9	1.1	-8.6	-24.9	-5.1	3.6	2.9	2.9
Op. Profit Mgn % ⓘ	13.5	13.6	15.2	14	14.7	16.8	12.1	17.3	16.9	17.9	18.3
Net Profit Mgn % ⓘ	0.1	-0.4	3.5	3	1.1	-7.9	-31.5	-6	4.1	3	3
Debt to Equity ⓘ	1.2	0.4	0.4	0.4	0.7	0.8	0.3	0.1	0.1	0.3	0.2
Working Cap Days ⓘ	129	128	130	161	211	240	257	150	124	141	83
Cash Conv. Cycle ⓘ	-9	-18	-16	-3	10	22	38	26	26	23	21

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 2.90%

Sales growth is growing at healthy rate in last 3 years 21.77%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 7.61%

Latest Financials - Healthcare Global Enterprises Ltd.

	Standalone	Consolidated
TTM EPS (₹)	2.5	4.1
TTM Sales (₹ Cr.)	1,146	2,042
BVPS (₹.) ⓘ	87.6	61.8
Reserves (₹ Cr.) ⓘ	1,059	722
P/BV ⓘ	6.06	8.59
PE ⓘ	215.81	129.87

From the Market
52 Week Low / High (₹)	310.10 / 553.25
All Time Low / High (₹)	62.95 / 547.25
Market Cap (₹ Cr.)	7,406
Equity (₹ Cr.)	139.4
Face Value (₹)	10
Industry PE ⓘ	43.2

Management X-Ray of HealthcareGlobal:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

3.00

3.09

0.00

3.09

* Pledged shares as % of Promoter's holding (%)

Valuation of HealthcareGlobal

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of HealthcareGlobal

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	420	471	545	586	640	688	609	850	1,006	1,099
Operating Expenses ⓘ	364	407	462	504	546	573	535	703	837	903
Manufacturing Costs	120	141	158	159	192	215	196	241	273	296
Material Costs	131	134	149	155	153	147	138	210	236	246
Employee Cost	69	85	98	116	130	143	137	157	175	197
Other Costs ⓘ	43	48	57	75	71	69	65	95	153	164
Operating Profit ⓘ	56	64	83	82	94	116	73	147	169	196
Operating Profit Margin (%)	13.4%	13.5%	15.2%	13.9%	14.7%	16.8%	12.1%	17.3%	16.8%	17.9%
Other Income ⓘ	4	3	7	23	13	12	24	12	22	17
Interest ⓘ	32	34	16	27	48	83	63	43	41	48
Depreciation ⓘ	33	37	44	44	47	79	87	88	89	94
Exceptional Items ⓘ	-4	-4	0	3	0	-31	-153	53	-3	-16
Profit Before Tax ⓘ	-8	-9	29	37	13	-65	-205	81	58	55
Tax ⓘ	-5	-4	10	12	5	-12	-14	43	17	21
Profit After Tax	-2	-5	19	25	7	-53	-192	38	40	34
PAT Margin (%)	-0.6%	-1.0%	3.6%	4.2%	1.1%	-7.7%	-31.5%	4.5%	4.0%	3.1%
Adjusted EPS (₹)	-0.3	-0.6	2.3	2.9	0.8	-6.0	-15.3	2.8	2.9	2.4
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	267	519	544	605	639	607	873	1,091	1,133	1,171
Share Capital ⓘ	70	85	86	87	88	89	125	139	139	139
Reserves ⓘ	197	434	458	518	551	519	748	952	994	1,032
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	277	160	165	219	396	419	214	83	113	362
Long Term Debt	247	123	124	217	346	315	147	82	113	261
Short Term Debt	29	37	41	2	50	104	67	1	0	101
Trade Payables	75	97	105	114	106	99	81	96	109	132
Others Liabilities ⓘ	70	60	96	165	259	628	379	374	375	523
Total Liabilities ⓘ	689	836	910	1,103	1,400	1,754	1,547	1,644	1,730	2,188
Fixed Assets
Gross Block	566	467	511	591	693	1,141	1,058	1,177	1,275	1,510
Accumulated Depreciation	162	36	69	99	146	227	313	403	487	572
Net Fixed Assetsⓘ	405	431	442	492	547	914	745	774	788	938
CWIP ⓘ	28	29	33	79	104	44	28	5	9	36
Investmentsⓘ	84	155	141	219	299	316	366	439	475	506
Inventories	13	11	15	17	16	13	12	17	21	21
Trade Receivables	64	69	101	126	146	152	147	160	212	204
Cash Equivalents	13	50	75	15	9	15	14	120	80	237
Others Assetsⓘ	83	91	103	155	280	300	235	129	144	244
Total Assets ⓘ	689	836	910	1,103	1,400	1,754	1,547	1,644	1,730	2,188

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	51	58	54	66	87	86	71	124	130	195
PBT ⓘ	-8	-9	29	37	13	-65	-205	81	58	55
Adjustment ⓘ	64	74	57	60	91	192	285	79	150	168
Changes in Working Capital ⓘ	-5	-0	-25	-32	10	-20	-49	-21	-60	5
Tax Paid ⓘ	0	-8	-7	1	-26	-20	40	-15	-17	-33
Cash Flow From Investing Activity ⓘ	-74	-86	-73	-185	-208	-116	-246	49	-138	-249
Capex	-67	-90	-40	-104	-123	-80	-23	-42	-95	-124
Net Investments	-5	-3	2	20	-15	4	-102	189	-10	-46
Others ⓘ	-2	7	-35	-100	-70	-40	-120	-99	-32	-79
Cash Flow From Financing Activityⓘ	22	120	-14	91	66	-3	236	-41	-42	105
Net Proceeds from Shares ⓘ	10	271	7	35	0	20	453	132	1	2
Net Proceeds from Borrowing ⓘ	29	-110	-9	79	106	36	-219	-67	14	174
Interest Paid ⓘ	-28	-33	-12	-23	-40	-66	-59	-43	-36	-46
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	12	-8	0	0	0	7	62	-63	-21	-25
Net Cash Flow ⓘ	-1	92	-33	-27	-55	-32	61	132	-49	51

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	-0.9	-1.2	3.67	4.33	1.16	-8.55	-25.87	3.9	3.61	2.95
ROCE (%)	4.42	3.98	6.12	7.65	6.13	1.62	-12.55	10.46	8.02	7.21
Asset Turnover Ratio	0.64	0.62	0.62	0.58	0.51	0.44	0.37	0.53	0.6	0.56
PAT to CFO Conversion(x)	N/A	N/A	2.84	2.64	12.43	N/A	N/A	3.26	3.25	5.74
Working Capital Days
Receivable Days	50	52	57	71	77	79	90	66	68	69
Inventory Days	10	9	9	10	10	8	7	6	7	7
Payable Days	189	235	248	259	263	256	238	154	159	179

Healthcare Global Enterprises Ltd Stock News

Healthcare Global Enterprises Ltd FAQs

What is the share price of HealthcareGlobal?

Company share prices are keep on changing according to the market conditions. The closing price of HealthcareGlobal on 20-Dec-2024 16:59 is ₹531.3.

What is the market cap of HealthcareGlobal?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of HealthcareGlobal stood at ₹7,406.5.

What is the P/E ratio of HealthcareGlobal?

The latest P/E ratio of HealthcareGlobal as of 20-Dec-2024 16:59 is 215.8.

What is the P/B ratio of HealthcareGlobal?

The latest P/B ratio of HealthcareGlobal as of 20-Dec-2024 16:59 is 6.06.

What is the 52-week high and low of HealthcareGlobal?

The 52-week high of HealthcareGlobal is ₹553.2 and the 52-week low is ₹310.1.

What is the TTM revenue of HealthcareGlobal?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of HealthcareGlobal is ₹1,146 ( Cr.) .

About Healthcare Global Enterprises Ltd

Healthcare Global Enterprises was originally incorporated as Curie Centre of Oncology Private Limited on March 12, 1998 at Bengaluru, Karnataka, India as a private limited company under the Companies Act, 1956. The name of the company was subsequently changed to HealthCare Global Enterprises Private Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on November 14, 2005. The company was converted into a public limited company pursuant to a special resolution passed by its Shareholders at the extraordinary general meeting held on May 20, 2006 and the name of the company was changed to HealthCare Global Enterprises Limited. A fresh certificate of incorporation consequent upon conversion to a public limited company was issued by the RoC on July 5, 2006.

The company is a provider of speciality healthcare services in India focused on cancer and fertility. Under the “HCG” brand, it operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed by the AERB . Under the “Milann” brand, it operates its fertility centres.

The company’s HCG network operates on a “hub and spoke” model, wherein its HCG centre of excellence in Bengaluru serves as a “hub” to its other cancer centres. Its centre of excellence provides its other centres access to centralised quality control and assurance services; establishes treatment protocols that are adhered to across its HCG network; provides centralised treatment planning and tele-radiology services to help with diagnosis and treatment; conducts weekly central tumour board meetings to review complex cases; and also gives its HCG network access to advanced technologies, such as WBRRS and specialised procedures such as liver transplants and stem cell therapies. This model allows HCG network of cancer centres to leverage the expertise and capabilities of its centre of excellence, which when combined with the diagnostic and treatment facilities at its cancer centres, allows it to deliver quality cancer care to patients across India in a seamless manner.

The company follows a multidisciplinary approach to cancer care across its HCG network, wherein specialist physicians from various disciplines collaborate to provide the best course of treatment for each patient. This allows it to share and develop best practices, build clinical expertise and adopt standardised protocols for diagnosis and treatment, thereby improving the quality of its cancer care services. As a result, the company is able to better serve its patients and ensure consistent clinical outcomes.

Given the large number of patient cases treated across its HCG network, the company is able to efficiently utilise its equipment, technologies and human resources, thereby deriving economies of scale. Furthermore, through the adoption of a centralised drug and consumables formulary, it is able to lower the overall cost of drugs and consumables. Its business model is scalable and when combined with efficient utilisation of resources, it enables it to operate within a competitive cost structure.

Business area of the company

The company is Bangalore based provider of speciality healthcare in India focused on cancer and fertility. It operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed. It also operates fertility centres under the ‘Milann’ brand.

Major events and milestones

2005: Entered into the clinical laboratory business through acquisition of Triesta Sciences Inc. and Triesta Sciences (India) Private Limited.
2006: India Development Fund made its first investment of Rs 500 million in the company,
2006: BMORCL became its subsidiary.
2007: HCG Medi-Surge became its subsidiary.
2007: Evolvence made its first investment of Rs 225 million in the company,
2008: NTICPL made its first investment of Rs 400 million in the company.
2009: Amalgamation of Triesta Sciences (India) Private Limited and Triesta Sciences Inc. with the company.
2010: IL&FS Trust Company Limited a/c MPEF, through its scheme India Build Out Fund I and MAT made its first investment of Rs 312 million in the company.
2011: Amalgamation of BMORCL with the company.
2011: PIOF became a Shareholder by purchasing shares from NTICPL.
2013: V-Sciences made its first investment of Rs 600 million in the company.
2013: Entered into the fertility business through acquisition of 50.10% stake in BACC Healthcare.
2014: Demerger of multispecialty division from HCG Medi-Surge and vesting of the same with the company.
2015: HCG Regency became its subsidiary.
2015: Amalgamation of HCG Vijay with the company.

Awards and accreditations

2010: The company received the ‘Oncology Leader of the Year’ award from Frost and Sullivan.
2011: The company and its Triesta Reference Laboratory received CAP accreditation valid up to August 25, 2015.
2011: The company received the ‘Oncology Leader of the Year’ award from Frost and Sullivan.
2012: HCG cancer centre at Bengaluru received NABH accreditation valid up to May 11, 2018.
2013: The company received the ‘Best Place to Work in Indian Healthcare’ award from People Strong and HOSMAC.
2013: HMS, Ahmedabad received NABH accreditation valid up to June 22, 2016.
2013: Triesta Reference Laboratory received accreditation from the National Accreditation Board for Testing and Caliberation Laboratories for its facilities at HCG Tower, Bengaluru in the field of medical testing valid up to October 13, 2015.
2013: The company was designated an ESMO Designated Centre of Integrated Oncology and Palliative Care.
2013: The company received the ‘Most Innovative Single Specialty Healthcare Entity’ award from VC Circle.
2014: The company received the ‘Golden Peacock Award for Innovation in Management’ from the Institute of Directors.
2014: Its pathology laboratory at HMS received ISO 9001 certification valid up to August 30, 2017.
2015: The company received recognition from the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India for its in-house research and development wing at HCG Tower, Bengaluru.